**ClinicalTrials.gov Search Results 04/07/2020**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Title | Status | Study Results | Conditions | Interventions | Locations |
| 1 | [Tarceva and AT-101 for Patients With Advanced Non-Small](https://ClinicalTrials.gov/show/NCT00934076) [Cell Lung Cancer](https://ClinicalTrials.gov/show/NCT00934076) | Withdrawn | No Results Available | * Carcinoma, Non Small Cell Lung | * Drug: Tarceva plus AT-101 |  |
| 2 | [Erlotinib and AT-101 in Advanced Non-Small Cell Lung](https://ClinicalTrials.gov/show/NCT00988169) [Cancer (NSCLC) Patients With Epidermal Growth Factor](https://ClinicalTrials.gov/show/NCT00988169) [Receptor (EGFR) Activating Mutations](https://ClinicalTrials.gov/show/NCT00988169) | Terminated | Has Results | * Lung Cancer | * Drug: oral erlotinib and pulsed doses of oral AT-101 | * Memorial Sloan Kettering Cancer Center, New York, New York, United States |
| 3 | [An Open-label, Single-center, Phase 1/ 2 Study of](https://ClinicalTrials.gov/show/NCT00561197) [Chemoradiotherapy and AT-101 in Patients With Locally](https://ClinicalTrials.gov/show/NCT00561197) [Advanced Esophageal or Gastroesophageal Junction Cancer](https://ClinicalTrials.gov/show/NCT00561197) | Terminated | No Results Available | * Locally Advanced Esophageal or GE Junction Cancer | * Drug: AT-101 | * MD Anderson Cancer Center, Houston, Texas, United States |
| 4 | [Phase 2 Safety and Efficacy Study of AT-101 in Combination](https://ClinicalTrials.gov/show/NCT00286780) [With Rituximab in Patients With Chronic Lymphocytic](https://ClinicalTrials.gov/show/NCT00286780) [Leukemia](https://ClinicalTrials.gov/show/NCT00286780) | Completed | No Results Available | * Chronic Lymphocytic Leukemia | * Drug: AT-101 | * UCSD Moores Cancer Center, San Diego, California, United States |
| 5 | [Safety and Efficacy Study of AT-101 in Combination With](https://ClinicalTrials.gov/show/NCT00286793) [Docetaxel and Prednisone in Men With HRPC](https://ClinicalTrials.gov/show/NCT00286793) | Completed | No Results Available | * Prostate Cancer | * Drug: AT-101 | * Hot Springs, Arkansas, United States * Fort Meyers, Florida, United States * Chicago, Illinois, United States * Fridley, Minnesota, United States * Albuquerque, New Mexico, United States * Syracuse, New York, United States * Wilmington, North Carolina, United States * Portland, Oregon, United States * Hilton Head Island, South Carolina, United States * Germantown, Tennessee, United States * and 3 more |
| 6 | [Lenalidomide and AT-101 in Treating Patients With Relapsed](https://ClinicalTrials.gov/show/NCT01003769) [B-Cell Chronic Lymphocytic Leukemia](https://ClinicalTrials.gov/show/NCT01003769) | Active, not recruiting | No Results Available | * Recurrent Chronic Lymphocytic Leukemia | * Drug: Lenalidomide * Drug: R-(-)-Gossypol Acetic Acid * Other: Laboratory Biomarker Analysis | * Mayo Clinic in Florida, Jacksonville, Florida, United States * Roswell Park Cancer Institute, Buffalo, New York, United States |
| 7 | [A Study of AT-101 in Combination With Docetaxel in](https://ClinicalTrials.gov/show/NCT01285635) [Squamous Cell Carcinoma Of The Head and Neck](https://ClinicalTrials.gov/show/NCT01285635) | Terminated | Has Results | * Squamous Cell Carcinoma of the Head and Neck (SCCHN) | * Drug: AT-101 * Drug: Docetaxel | * University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States * Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States |
| 8 | [A Study Comparing AT-101 in Combination With Docetaxel](https://ClinicalTrials.gov/show/NCT00571675) [and Prednisone Versus Docetaxel and Prednisone in Men](https://ClinicalTrials.gov/show/NCT00571675) [With Chemotherapy-Naïve Metastatic Hormone Refractory](https://ClinicalTrials.gov/show/NCT00571675) [Prostate Cancer (HRPC)](https://ClinicalTrials.gov/show/NCT00571675) | Completed | No Results Available | * Hormone Refractory Prostate Cancer | * Drug: AT-101, prednisone and docetaxel * Drug: placebo, prednisone and docetaxel | * Colorado Springs, Colorado, United States * New Port Richey, Florida, United States * Ocoee, Florida, United States * Fishers, Indiana, United States * Burnsville, Minnesota, United States * Las Vegas, Nevada, United States * Albuquerque, New Mexico, United States * Las Cruces, New Mexico, United States * Raleigh, North Carolina, United States * Kettering, Ohio, United States * and 25 more |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Title | Status | Study Results | Conditions | Interventions | Locations |
| 9 | [A Randomized Phase 2 Study of AT-101 in Combination](https://ClinicalTrials.gov/show/NCT00544960) [With Docetaxel in Relapsed/Refractory Non-Small Cell Lung](https://ClinicalTrials.gov/show/NCT00544960) [Cancer](https://ClinicalTrials.gov/show/NCT00544960) | Completed | No Results Available | * Non-small Cell Lung Cancer | * Drug: AT-101 and docetaxel * Drug: placebo and docetaxel | * Research Site, Durham, North Carolina, United States * Research Site, Arkhangelsk, Russian Federation * Research Site, Chelyabinsk, Russian Federation * Research Site, Ekaterinburg, Russian Federation * Research Site, Kaliningrad, Russian Federation * Research Site, Kazan, Russian Federation * Research Site, Moscow, Russian Federation * Research Sites (4), Saint Petersburg, Russian Federation * Research Site, Samara, Russian Federation * Research Site, Stavropol, Russian Federation * and 8 more |
| 10 | [Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ](https://ClinicalTrials.gov/show/NCT01633541) [Preservation In Adults With Advanced Laryngeal Cancer](https://ClinicalTrials.gov/show/NCT01633541) | Active, not recruiting | No Results Available | * Laryngeal Cancer | * Drug: AT-101 * Drug: Docetaxel * Drug: Cisplatin * Drug: Carboplatin | * University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States |
| 11 | [Study of AT-101 in Combination With Topotecan in Relapsed/](https://ClinicalTrials.gov/show/NCT00397293) [Refractory Small Cell Lung Cancer](https://ClinicalTrials.gov/show/NCT00397293) | Completed | No Results Available | * Small Cell Lung Cancer | * Drug: AT-101 * Drug: topotecan | * Birmingham, Alabama, United States * Hot Springs, Arkansas, United States * Loma Linda, California, United States * Stamford, Connecticut, United States * Jacksonville, Florida, United States * Lake City, Florida, United States * Boston, Massachusetts, United States * Rochester, Minnesota, United States * Lebanon, New Hampshire, United States * High Point, North Carolina, United States * and 9 more |
| 12 | [Gossypol Acetic Acid in Treating Patients With Recurrent,](https://ClinicalTrials.gov/show/NCT00848016) [Metastatic, or Primary Adrenocortical Cancer That Cannot Be](https://ClinicalTrials.gov/show/NCT00848016) [Removed By Surgery](https://ClinicalTrials.gov/show/NCT00848016) | Completed | Has Results | * Recurrent Adrenocortical Carcinoma * Stage III Adrenocortical Carcinoma * Stage IV Adrenocortical Carcinoma | * Drug: R-(-)-gossypol acetic acid | * University of Southern California, Los Angeles, California, United States * Mayo Clinic, Rochester, Minnesota, United States |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Title | Status | Study Results | Conditions | Interventions | Locations |
| 13 | [Safety & Efficacy Study of AT-101 in Combination w/](https://ClinicalTrials.gov/show/NCT00440388) [Rituximab in Previously Untreated Grade I-II Follicular Non-](https://ClinicalTrials.gov/show/NCT00440388) [Hodgkin's Lymphoma](https://ClinicalTrials.gov/show/NCT00440388) | Completed | No Results Available | * Follicular Lymphoma | * Drug: AT-101 * Drug: Rituximab | * University of Alabama at Birmingham, Birmingham, Alabama, United States * Hematology Oncology Associates, Phoenix, Arizona, United States * Rocky Mountain Cancer Center-Aurora, Aurora, Colorado, United States * Florida Cancer Institute, Hudson, Florida, United States * Florida Cancer Institute, New Port Richey, Florida, United States * Cancer Care & Hematology Specialists of Chicagoland, Arlington Heights, Illinois, United States * Central Indiana Cancer Centers, Fishers, Indiana, United States * University of Michigan Cancer Center, Ann Arbor, Michigan, United States * Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States * Missouri Cancer Associates, Columbia, Missouri, United States * and 18 more |
| 14 | [Phase II Safety and Efficacy Study of Single-agent AT-101 in](https://ClinicalTrials.gov/show/NCT00275431) [Patients With Relapsed or Refractory B-cell Malignancies](https://ClinicalTrials.gov/show/NCT00275431) | Completed | No Results Available | * Follicular Lymphoma * Diffuse Large Cell Lymphoma * Mantle Cell Lymphoma * Small Lymphocytic Lymphoma * Chronic Lymphocytic Leukemia | * Drug: AT-101 | * Birmingham, Alabama, United States * San Diego, California, United States * Atlanta, Georgia, United States * Chicago, Illinois, United States * Boston, Massachusetts, United States * New York, New York, United States * Rochester, New York, United States * High Point, North Carolina, United States * Hilton Head Island, South Carolina, United States * Memphis, Tennessee, United States * Burlington, Vermont, United States |
| 15 | [A Study of Single-Agent AT-101 in Men With Hormone](https://ClinicalTrials.gov/show/NCT00286806) [Refractory Prostate Cancer](https://ClinicalTrials.gov/show/NCT00286806) | Completed | No Results Available | * Hormone Refractory Prostate Cancer | * Drug: AT-101 | * Greenbrae, California, United States * New Haven, Connecticut, United States * Memphis, Tennessee, United States * Madison, Wisconsin, United States |
| 16 | [R-(-)-Gossypol Acetic Acid With Lenalidomide and](https://ClinicalTrials.gov/show/NCT02697344) [Dexamethasone in Treating Patients With Relapsed](https://ClinicalTrials.gov/show/NCT02697344) [Symptomatic Multiple Myeloma](https://ClinicalTrials.gov/show/NCT02697344) | Active, not recruiting | No Results Available | * Recurrent Plasma Cell Myeloma | * Drug: Dexamethasone * Other: Laboratory Biomarker Analysis * Drug: Lenalidomide * Other: Pharmacological Study * Drug: R-(-)-Gossypol Acetic Acid | * Mayo Clinic in Florida, Jacksonville, Florida, United States |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Title | Status | Study Results | Conditions | Interventions | Locations |
| 17 | [Gossypol in Treating Patients With Progressive or Recurrent](https://ClinicalTrials.gov/show/NCT00540722) [Glioblastoma Multiforme](https://ClinicalTrials.gov/show/NCT00540722) | Completed | Has Results | * Adult Giant Cell Glioblastoma * Adult Glioblastoma * Adult Gliosarcoma * Recurrent Adult Brain Tumor | * Drug: R-(-)-gossypol acetic acid * Other: laboratory biomarker analysis | * University of Alabama at Birmingham, Birmingham, Alabama, United States * Moffitt Cancer Center, Tampa, Florida, United States * Johns Hopkins University, Baltimore, Maryland, United States * Massachusetts General Hospital, Boston, Massachusetts, United States * Henry Ford Hospital, Detroit, Michigan, United States * Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States * Cleveland Clinic Foundation, Cleveland, Ohio, United States * University of Pennsylvania, Philadelphia, Pennsylvania, United States |
| 18 | [R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in](https://ClinicalTrials.gov/show/NCT00544596) [Treating Patients With Advanced Solid Tumors or Extensive](https://ClinicalTrials.gov/show/NCT00544596) [Stage Small Cell Lung Cancer](https://ClinicalTrials.gov/show/NCT00544596) | Completed | No Results Available | * Extensive Stage Small Cell Lung Cancer * Unspecified Adult Solid Tumor, Protocol Specific | * Drug: R-(-)-gossypol acetic acid * Drug: cisplatin * Drug: etoposide | * Sanford Cancer Center-Oncology Clinic, Sioux Falls, South Dakota, United States * Gundersen Lutheran, La Crosse, Wisconsin, United States * UW Health Oncology - 1 South Park, Madison, Wisconsin, United States * University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States |
| 19 | [R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent](https://ClinicalTrials.gov/show/NCT00773955) [Extensive-Stage Small Cell Lung Cancer](https://ClinicalTrials.gov/show/NCT00773955) | Completed | Has Results | * Extensive Stage Small Cell Lung Cancer * Recurrent Small Cell Lung Cancer | * Drug: R-(-)-gossypol acetic acid * Other: pharmacological study * Other: laboratory biomarker analysis | * Mayo Clinic, Rochester, Minnesota, United States |
| 20 | [R-(-)-Gossypol and Androgen Ablation Therapy in Treating](https://ClinicalTrials.gov/show/NCT00666666) [Patients With Newly Diagnosed Metastatic Prostate Cancer](https://ClinicalTrials.gov/show/NCT00666666) | Completed | Has Results | * Adenocarcinoma of the Prostate * Stage IV Prostate Cancer | * Drug: AT-101 * Drug: Bicalutamide * Other: LHRH agent | * University of Chicago, Chicago, Illinois, United States * University of Michigan, Ann Arbor, Michigan, United States * Cancer Institute of New Jersey, New Brunswick, New Jersey, United States * University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Title | Status | Study Results | Conditions | Interventions | Locations |
| 21 | [Gossypol, Paclitaxel, and Carboplatin in Treating Patients](https://ClinicalTrials.gov/show/NCT00891072) [With Solid Tumors That Are Metastatic or Cannot Be](https://ClinicalTrials.gov/show/NCT00891072) [Removed by Surgery](https://ClinicalTrials.gov/show/NCT00891072) | Completed | No Results Available | * Adult Grade III Lymphomatoid Granulomatosis * Adult Nasal Type Extranodal NK/T-cell Lymphoma * Contiguous Stage II Adult Burkitt Lymphoma * Contiguous Stage II Adult Diffuse Large Cell Lymphoma * Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma * Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma * Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma * Contiguous Stage II Adult Lymphoblastic Lymphoma * Contiguous Stage II Grade 1 Follicular Lymphoma * Contiguous Stage II Grade 2 Follicular Lymphoma * and 71 more | * Drug: R-(-)-gossypol acetic acid * Drug: paclitaxel * Drug: carboplatin * Other: pharmacological study | * Cancer Institute of New Jersey, New Brunswick, New Jersey, United States |
| 22 | [Gossypol (AT-101) and Temozolomide With or Without](https://ClinicalTrials.gov/show/NCT00390403) [Radiation Therapy in Treating Patients With Newly Diagnosed](https://ClinicalTrials.gov/show/NCT00390403) [Glioblastoma Multiforme](https://ClinicalTrials.gov/show/NCT00390403) | Completed | No Results Available | * Brain and Central Nervous System Tumors | * Drug: R-(-)-gossypol acetic acid * Drug: temozolomide * Genetic: gene expression analysis * Genetic: mutation analysis * Genetic: protein expression analysis * Other: laboratory biomarker analysis * Other: pharmacological study * Procedure: adjuvant therapy * Radiation: radiation therapy | * Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama, United States * H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States * Winship Cancer Institute of Emory University, Atlanta, Georgia, United States * Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States * Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States * Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States * Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States * Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States |
| 23 | [Gossypol Combined With Docetaxel and Cisplatin Scheme](https://ClinicalTrials.gov/show/NCT01977209) [in Advanced Non Small-cell Lung Cancers With APE1 High](https://ClinicalTrials.gov/show/NCT01977209) [Expression](https://ClinicalTrials.gov/show/NCT01977209) | Unknown status | No Results Available | * Non-small Cell Lung Cancer | * Drug: Gossypol * Drug: Placebo | * Daping Hospital, Third Military Medical University, Chongqing, Chongqing, China * Chongqing Zhongshan Hospital, Chongqing, Chongqing, China * Fuling Central Hospital, Chongqing, Chongqing, China * Jiangjin Central Hospital, Chongqing, Chongqing, China * The Second Affiliated Hospital of Medical University Of Chongqing, Chongqing, Chongqing, China * Three Gorges Central Hospital, Chongqing, Chongqing, China |
| 24 | [Investigation of AAI101 Safety, Tolerability & PK in Healthy](https://ClinicalTrials.gov/show/NCT03685084) [Volunteers](https://ClinicalTrials.gov/show/NCT03685084) | Completed | No Results Available | * Healthy | * Drug: AAI101 i.v. * Drug: Saline 0.9% infusion * Drug: Piperacillin i.v. * Drug: Cefepime i.v. |  |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Title | Status | Study Results | Conditions | Interventions | Locations |
| 25 | [A Study of DCR-A1AT in Healthy Adult Volunteers and](https://ClinicalTrials.gov/show/NCT04174118) [Patients With A1ATD-Associated Liver Disease](https://ClinicalTrials.gov/show/NCT04174118) | Recruiting | No Results Available | * Alpha 1-Antitrypsin Deficiency | * Drug: DCR-A1AT * Drug: Placebo | * Clinical Trial Consultants AB, Uppsala, Sweden |
| 26 | [Gastric Acid Rebound Secretion Measured by Alkaline Tide](https://ClinicalTrials.gov/show/NCT01315444) | Withdrawn | No Results Available | * Condition Measuring Alkaline Tide and Filling Symptoms' Questionnaire After Abrupt or Gradual Step Down Cessation of PPI | * Drug: Stop PPI gradually |  |
| 27 | [Study of the Safety, Tolerability, Pharmacokinetics and](https://ClinicalTrials.gov/show/NCT01265199) [Pharmacodynamic Properties of Oral AT-406 in Combination](https://ClinicalTrials.gov/show/NCT01265199) [With Daunorubicin and Cytarabine in Patients With Poor-risk](https://ClinicalTrials.gov/show/NCT01265199) [Acute Myelogenous Leukemia (AML)](https://ClinicalTrials.gov/show/NCT01265199) | Terminated | No Results Available | * Acute Myelogenous Leukemia (AML) | * Drug: AT-406 in combination with daunorubicin and cytarabine | * Univerity of Chicago, Chicago, Illinois, United States * University of Michigan Health System, Ann Arbor, Michigan, United States * Washington University at St. Louis Siteman Cancer Center, St. Louis, Missouri, United States * Memorial Sloan Kettering Cancer Center, New York, New York, United States * Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States * Temple University at Jeanes Hospital, Philadelphia, Pennsylvania, United States |
| 28 | [A Randomized Trial of Vaccine Adherence in Young Injection](https://ClinicalTrials.gov/show/NCT00244374) [Drug Users](https://ClinicalTrials.gov/show/NCT00244374) | Completed | Has Results | * Medication Adherence * Substance Abuse, Intravenous * Risk Behavior * Hepatitis A * Hepatitis B * Hepatitis C | * Biological: Hepatitis A & B vaccine * Behavioral: Outreach * Behavioral: AIC * Behavioral: SEP | * University of California San Francisco Medical Cen, San Francisco, California, United States |

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services